We are a rapidly growing venture capital-backed medical technology startup. Ceribell is being used in hundreds of community hospitals, large academic facilities and major IDN’s across the country. With extensive clinical validation of the effectiveness of our product and significant growth potential, Ceribell is a fantastic career opportunity.
\nPosition Overview
\nThe Clinical Account Manager (CAM) is responsible for launching new hospitals and organic growth of install base of hospitals. The AM will also be responsible for providing on-going medical education to physicians and clinical staff using clinical information as the foundation for growth.
\nThis Clinical Account Manager must be based within region, please no remote applicants.
\nWhat You'll Do
\nDriving New and Organic Growth
\nClinical Training / Education
\nReporting and Administration
\nWhat We're Looking For
\nApplication Deadline: Ongoing
\nA candidate’s final salary offer will be based on their skills, education, work location and experience, and thus it may differ from the posted range. Compensation may also include bonuses consistent with Ceribell’s corporate compensation plan. Note, the above description is not all-encompassing and Ceribell reserves the right to change or modify job duties and assignments at any time.
\nCeribell is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex (including pregnancy, childbirth and related medical conditions), sexual orientation, gender identity or expression, national origin, age, marital status, disability, veteran status or any other characteristic protected by law. Any applicant with a disability who requires an accommodation during the application process should contact talent@ceribell.com to request reasonable accommodation.
\n#LI-EK1
What We Offer
Full-Time
EEG devices for monitoring brain activity
$100k - $180k/yr
Mid, Senior
Omaha, NE, USA
Upload your resume to see how it matches 4 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data on brain activity, which is essential for diagnosing and treating neurological conditions, particularly in urgent situations like Nonconvulsive Status Epilepticus (NCSE). Unlike some other medical devices, the Ceribell EEG Recorder does not provide diagnostic conclusions or automated alerts; instead, it serves as a tool for healthcare professionals to collect data for interpretation. Ceribell generates revenue by selling these devices to healthcare providers, adhering to regulations that require physician orders for their use. The company's goal is to enhance the speed and effectiveness of treatment for patients experiencing critical neurological events.
Company Size
201-500
Company Stage
Series C
Total Funding
$171M
Headquarters
Mountain View, California
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Annual Bonus Opportunity
Company Equity
Phone/Internet Stipend
CeriBell's (NASDAQ:CBLL) lock-up period ends on April 9th, allowing major shareholders and insiders to trade shares. The company issued 10,606,060 shares in its IPO on October 11th, raising $180 million at $17 per share. Analysts have given CBLL a consensus "Buy" rating with a $32.50 price target. The stock opened at $18.19, with a 52-week range of $17.24 to $32.75. Recent earnings missed estimates, reporting a loss of $0.40 per share on $18.53 million revenue.
—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. “Ms
Ceribell, a former Fierce Medtech Fierce 15 honoree, has been developing a point-of-care electroencephalography platform that combines a disposable, brain-reading headset with artificial intelligence-powered algorithms that help detect hidden seizures-also known as electrographic status epilepticus, or ESE.
CeriBell, a medical device maker with an EEG platform that uses AI to monitor patient seizures, announced terms for its IPO on Monday.
Healthcare sales veteran to lead sales strategies and initiatives to propel continued commercial growthSUNNYVALE, Calif., April 2, 2024 /PRNewswire/ -- Today, Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG diagnostic system, announced the appointment of Sean Manni as Senior Vice President of Sales. In this role, Mr. Manni will lead Ceribell's commercial sales organization as it continues to expand its U.S. footprint."Sean brings an impressive blend of accomplishments, strategy, and leadership that will undoubtedly elevate our entire commercial organization," said Ceribell co-founder and CEO Jane Chao, Ph.D. "His guidance will be instrumental in developing and executing our plans to further expand our market presence in the U.S., ultimately benefiting patients by increasing access to our groundbreaking technology.""Joining Ceribell represents a unique opportunity to collaborate with an exceptional leadership and sales team," said Manni. "I am deeply committed to leveraging my experience in healthcare sales to further innovate Ceribell's sales strategies and ensure our revolutionary AI-powered point-of-care EEG solutions reach patients in need."Mr